State treasurer balks at State Health Plan coverage of weight loss drugs
The increasingly high cost of certain popular weight-loss drugs, such as Wegovy and Saxenda, has prompted state Treasurer
The SHP is
It covers nearly 740,000 teachers, state employees, legislators, retirees and their dependents. The state treasurer's office oversees the plan.
Folwell said in a statement Tuesday his recommendation to the SHP board of trustees is based on how global pharmaceutical manufacturer
The weight-loss medications are being currently used by more than
"It defies logic that
"They should be investigated by the
Wegovy, which contains the active ingredient semaglutide, is specifically approved for chronic weight management.
Semaglutide imitates a hormone called glucagon-like peptide-1 (GLP-1), which prompts the body to produce more insulin and makes a person feel satiated, according to an
The ingredient has been shown to help people lose an average of about 15% of their weight.
According to the treasurer's office, the SHP spent
SHP spending on the two medications is projected to exceed
Folwell's recommendation comes as the SHP faces a
The Republican sponsored 2023-24 state budget provides
Under Folwell's direction, the SHP has attempted to remain financially solvent by capping or reducing its costs as much as possible, and by implementing strategic initiatives that seek to maintain or lower dependent premiums to attract younger members and families.
SHP staff estimates that continuing to cover this class of drugs for weight loss will result in a premium increase of
"We are not questioning the efficacy of the drugs, but we simply can't afford these medications at the manufacturer's current price point," Folwell said.
"It's price gouging. We just want to pay the same price that
According to the
Medicare has been explicitly forbidden by law from providing coverage for weight-loss treatments since 2003.
The ban was implemented in part because of concerns over the safety of weight-loss drugs at the time, such as the combination of fenfluramine and phentermine, or fen-phen, which was associated with life-threatening hypertension and heart valve issues.
There are other potential side effects with semaglutide medications that include nausea, fatigue, lightheadedness, decreased muscle mass and chronic paralysis of the digestive system.


Advanced Health Intelligence grants 90-day extension to Changlin Network Technology Ltd Exclusive License – Form 6-K
Fraudulent life insurance policies paid off only for Miami insurance agents, state says [Miami Herald]
Advisor News
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
More Annuity NewsHealth/Employee Benefits News
- Vt. public schools expect the lowest health insurance increase in years
- Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
- Reports Outline Managed Care Study Results from Harvard University (Inpatient-Only List Removals Shifted Procedures To The Outpatient Setting And Reduced Medicare Spending): Managed Care
- Health and Humor: Picking a Medicare insurance plan is daunting
- Obamacare is getting more expensive in Indiana
More Health/Employee Benefits NewsLife Insurance News
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
- NAIC task force to address LTC riders
- Protective names Kurt Meyers Chief Legal Officer and Fernando Levy Chief Digital & AI Officer
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
More Life Insurance News